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Background
Pancreatic cancer is asymptomatic in nature and 
usually is not detected until metastasis has 
occurred. At Stage I, the five-year survival rate is 
34% but drops dramatically to 3% at Stage IV.1,2
Techniques can be used to analyze and compare 
metabolites as cancer tissue and normal tissue 
metabolize glucose differently.3 Targeting 
glutaminolysis, the breakdown of glutamine, 
through glutaminase inhibition can disrupt cancer 
metabolism and tumor progression.4 Therefore, 
analyzing the metabolic profile of pancreatic 
cancer can lead to early detection and therapeutic 
efficacy. 
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Methods
1. Specific pancreatic cancer tumors were 
collected from collaborators in the department
2. Four groups of pancreatic mice with KRAS, 
P53, and SMAD mutations were employed 
• One group was treated with 12.5 mg/kg of 
V9301 twice per day for 4 weeks (low 
dosage treatment) 
• Another group was treated with 75 mg/kg 
single bolus dose for 4 hours begore 
being sacrificed (high dosage treatment 
• A third and fourth group were control mice 
with pancreatic cancer that received a 
sham vehicle treatment (low and high 
dosage respectively) 
3. Frozen tumor samples are collected from 
these models and are pulverized using a 
biopulverizer
4. The samples were lysed using lysing ceramic 
beads in a 2:1 methanol−water solution to 
extract the metabolites
5. The solution was then evaporated using a 
rotovapor and lyophilizer and the remaining 
solvent was dissolved in D2O with a DSS 
reference
6. Nuclear magnetic resonance (NMR) 
spectroscopy (1D-proton) was performed on 
a 500 MHz Bruker Advance III HD NMR 
spectrometer
7. Data was analyzed for the specific 
metabolites and metabolic profiles in the 
tumor samples
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Objective
Through a blinded study, a metabolomic analysis of 
tumors from mouse models, utilizing nuclear 
magnetic resonance (NMR) spectroscopy, can be 
used to detect the presence of pancreatic cancer. 
This analysis can also determine the efficacy of 
using glutaminase-inhibition based treatment 
































































The levels of lactate, alanine, and glutamine were the main metabolites analyzed from the NMR 
spectroscopy. Lactate is a metabolite that is high in cancer cells, while alanine levels are low. 
Glutamine is an amino acid that causes tumor growth. Therefore, a glutaminase inhibitor reduces 
the levels of glutamine, which limits tumor progression. The results show changes in the levels of 
these three metabolites based on the various four groups of pancreatic mice:
• Group 1: Contains a high amount of lactate, but lower amounts of alanine and glutamine 
• Group 2: Contains a high amount of lactate and glutamine, and a medium amount of 
alanine 
• Group 3: Contains a low amount of lactate, a medium amount of alanine, and a low amount 
of glutamine 
• Group 4: Contains a medium amount of lactate, a high amount of alanine, and a low 
amount of glutamine
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Relation to Cancer Prevention 
This project contributes to the field of cancer 
prevention by studying alternative methods to 
detecting pancreatic cancer in its early stages. 
Ultimately, these novel methods, if used early 
enough, can detect pancreatic cancer before it 
occurs or prevent cancer from metastasizing and 
reaching later stages when they are usually deadly.
Conclusion
The results strongly indicate Group 1 and 2 in the study are the control groups. Group 1 most likely 
consisted of the mice that received the low dosage of the sham vehicle treatment, while Group 2 
the high dosage. Group 3 is predicted to be the group that received the high single bolus dosage of 
V9301 and Group 4 with the low dosage. This study provides evidence that comparing metabolites 
successfully detects the progression of cancer and determines the efficacy of novel treatments, 
such as a glutaminase-inhibitor based treatment. 
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